UNION therapeutics announces presentation of new data on orismilast at the 31[st] EADV Congress
· Oral presentation of new preclinical data on pharmacological properties of orismilast at the EADV Congress · Additional e-poster details the safety and efficacy of orismilast IR (immediate release) tablets in adults with moderate to severe psoriasis and the development of orismilast MR (modified release) tablets · Orismilast is a potent next-generation PDE4 inhibitor with broad anti-inflammatory properties in development for the treatment of psoriasis, atopic dermatitis (AD) and hidradenitis suppurativa (HS) Hellerup, Denmark, 19 August 2022 – UNION therapeutics A/S (UNION),